ESR1 and breast carcinoma: In contrast, a retrospective analysis of data from a multinational interventional study of 7576 postmenopausal individuals with estrogen receptor (ER)- and/or progesterone receptor (PR)+ breast cancer treated with AIs found no association between VMSs and relapse-free survival [46].